One Infusion, Permanent DNA Editing? CRISPR May Be Entering the Therapeutic Era
Over the past decade, the most frequently asked question about CRISPR has been: “Can it really treat disease?”
Today, that question is gradually shifting into something more fundamental: “If it can truly provide permanent cures, is humanity ready to accept it?”
On April 27, 2026, Intellia Therapeutics announced highly anticipated clinical results: its in vivo CRISPR therapy lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) met the primary endpoint in the Phase III HAELO trial, achieving an 87% reduction in attack rates in patients with hereditary angioedema (HAE).
The company has also initiated a rolling Biologics License Application (BLA) submission to the FDA. If approved, Intellia expects the therapy to enter the U.S. market as early as 2027, potentially making it one of the first commercially available in vivo CRISPR therapies worldwide.
01
One Infusion, No More Recurrent Attacks
HAE is a classic monogenic disorder. Due to dysfunction in the C1 inhibitor pathway, patients experience continuous overproduction of bradykinin, leading to markedly increased vascular permeability and recurrent swelling episodes. These can range from mild edema in the extremities and face to severe abdominal pain and, in extreme cases, life-threatening laryngeal edema and asphyxiation.
Globally, approximately 1 in 50,000 people are affected. Many patients live with the constant anxiety of unpredictable attacks. As a result, despite the availability of multiple preventive and on-demand therapies targeting different pathways, HAE remains fundamentally a chronically managed disease rather than one that can be truly cured at the disease level.
The HAELO trial is a randomized, double-blind, placebo-controlled Phase III study enrolling 80 patients with type I or II HAE (aged ≥16 years). Of these, 52 patients received a single 50 mg intravenous infusion of lonvo-z, while 28 received placebo.
During the six-month efficacy evaluation period (weeks 5 to 28), the lonvo-z group experienced an average monthly attack rate of 0.26, compared with 2.10 in the placebo group, representing an 87% reduction (p<0.0001).
Even more strikingly, 62% of patients in the treatment group remained completely attack-free throughout the evaluation period without requiring additional therapy, compared with only 11% in the placebo group.
As of February 10, 2026, all patients treated with lonvo-z had discontinued long-term prophylactic therapy. In terms of safety, no serious adverse events were observed. The most common adverse events were infusion-related reactions, headache, and fatigue, all of which were mild to moderate.
More importantly, this marks the first time CRISPR is advancing through a true “drug development” pathway—large-scale Phase III trials, regulatory review, and potential commercialization.
02
From Bradykinin Suppression to Pathway Rewriting
Current HAE therapies are fundamentally based on continuous suppression of bradykinin production. For example, Takhzyro is administered every two weeks; Orladeyo is taken daily as an oral therapy; and Dawnzera, despite extending dosing intervals to every 4–8 weeks, still requires lifelong administration.
Intellia's approach is far more radical: if the disease is driven by continuous bradykinin generation, why not directly eliminate the upstream genetic driver?
Lonvo-z uses lipid nanoparticles (LNPs) to deliver a CRISPR/Cas9 system directly into the liver, where it knocks out the KLKB1 gene. This gene encodes prekallikrein, a key component in the bradykinin production pathway.
In other words, rather than suppressing downstream symptoms, Intellia aims to permanently rewrite the disease circuitry at its source.
This is why in vivo gene editing has long been considered the ultimate form of CRISPR therapeutics. Early CRISPR therapies were primarily ex vivo approaches—cells are extracted, edited outside the body, and reinfused, as in Casgevy. While more controllable, this approach is complex, costly, and resembles a highly customized form of cellular therapy.
In vivo editing, by contrast, is much closer to a conventional drug model: a single intravenous infusion that performs genetic modification directly inside the body. In this sense, CRISPR is finally beginning to resemble a true “drug.”
03
Beyond Science: Fear, Time, and Reality
The promise of “one-time durable treatment” has always been one of the most compelling narratives in gene therapy. Yet reality has rarely matched expectations.
In recent years, the gene therapy sector has experienced a noticeable slowdown in commercial enthusiasm. A notable example is Roctavian from BioMarin Pharmaceutical. While scientifically significant, it fell short of commercial expectations—not due to lack of efficacy, but because both physicians and patients remain cautious about permanent biological modification.
Even Casgevy, the first approved CRISPR therapy, has seen gradual market adoption. Despite complex treatment procedures, chemotherapy conditioning, and risks such as fertility impairment, patients are slowly but steadily embracing the concept of a one-time curative approach. For upcoming in vivo editing therapies, this serves both as a benchmark and a psychological preview.
Permanent DNA editing follows a fundamentally different risk logic compared with conventional drugs. Traditional drugs can be discontinued if side effects occur; antibody therapies can be switched if efficacy declines.
But once gene editing is performed, it is, in principle, irreversible. CRISPR still carries risks such as off-target editing, immunogenicity, and unknown long-term safety outcomes. The industry's core concern is not short-term efficacy, but whether irreversible adverse effects could emerge years later.
This concern was further amplified in 2025, when Intellia's other CRISPR program, nex-z (nexiguran ziclumeran, for ATTR amyloidosis), experienced a patient death during a Phase III trial, leading to a temporary FDA clinical hold. Although the program has since resumed following updated risk mitigation measures, there is currently no evidence suggesting this risk extends to the lonvo-z program.
As a result, safety has become as important as efficacy in this Phase III dataset. For a therapy that permanently edits DNA inside the human body, the absence of serious adverse events is itself a highly meaningful signal.
Still, the true challenge is time. The questions facing Intellia are no longer purely scientific: Will patients accept permanent DNA editing? Will healthcare systems support therapies potentially priced in the million-dollar range? Will physicians replace established chronic treatments with one-time interventions? And how strict will regulators be regarding long-term follow-up requirements?
At the same time, Intellia is under increasing financial pressure. In Q1 2026, the company reported a net loss of $96.2 million and completed an additional $180 million financing round. As of March 2026, it held approximately $517 million in cash and marketable securities, expected to fund operations through 2028. This places the company in a critical transition phase—from a research-driven biotech into a fully commercial pharmaceutical company.
In many ways, lonvo-z is no longer just a new treatment for HAE—it has become a real-world experiment for the entire in vivo CRISPR field.
If successful, it could accelerate CRISPR's transition from frontier science to standard therapy. If the market remains cautious, however, it may also serve as a reminder that scientific feasibility does not always equate to societal readiness.
Reference
[1]. “Intellia heads to FDA with first in vivo CRISPR-based gene editing therapy.” Nature biotechnology vol. 44,5 (2026): 676. doi:10.1038/s41587-026-03154-9
[2]. Cohn, Danny M et al. “CRISPR-Based Therapy for Hereditary Angioedema.” The New England journal of medicine vol. 392,5 (2025): 458-467. doi:10.1056/NEJMoa2405734
[3]. High, Katherine A, and Maria G Roncarolo. “Gene Therapy.” The New England journal of medicine vol. 381,5 (2019): 455-464. doi:10.1056/NEJMra1706910
Contact us
+ 833-226-3234 (USA Toll-free)
+1-224-345-1927 (USA)
info@editxor.com
Tag
Share
